Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma

被引：0
|
作者：
Chen, Ru [1 ]
Pan, Sheng [1 ]
Maitra, Anirban [2 ]
Simeone, Diane [3 ]
Dawson, David [4 ]
Brentnall, Teresa [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] UT MD Anderson, Houston, TX USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2866
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2866
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Adjuvant Treatment of Surgically Resectable Pancreatic Ductal Adenocarcinoma
    Tesfaye, Anteneh A.
    Philip, Philip A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 54 - 63
  • [32] Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kaufmann, Benedikt
    Hartmann, Daniel
    D'Haese, Jan G.
    Stupakov, Pavel
    Radenkovic, Dejan
    Gloor, Beat
    Friess, Helmut
    DIGESTIVE SURGERY, 2019, 36 (06) : 455 - 461
  • [33] Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Bonds, Morgan
    Rocha, Flavio G.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [34] Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
    Cao, Ying-Ying
    Guo, Kai
    Zhao, Rui
    Li, Yuan
    Lv, Xiao-Jing
    Lu, Zi-Peng
    Tian, Lei
    Ren, Shuai
    Wang, Zhong-Qiu
    DIGITAL HEALTH, 2023, 9
  • [35] Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma
    Alvarez, R.
    Ales, I.
    Diaz, R.
    de Paredes, B. G.
    Hidalgo, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (10): : 1193 - 1198
  • [36] Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma
    R. Álvarez
    I. Alés
    R. Díaz
    B. G. de Paredes
    M. Hidalgo
    Clinical and Translational Oncology, 2017, 19 : 1193 - 1198
  • [37] Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
    Hartley, Christopher
    Rowan, Daniel
    Chen, Xiuxu
    Gomez-Arellano, Luisa
    West, Anna Marie
    Oshima, Kiyoko
    Mackinnon, Alexander Craig
    PRACTICAL LABORATORY MEDICINE, 2020, 21
  • [38] Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma
    Konishi, Takanori
    Takano, Shigetsugu
    Takayashiki, Tsukasa
    Suzuki, Daisuke
    Sakai, Nozomu
    Hosokawa, Isamu
    Mishima, Takashi
    Nishino, Hitoe
    Suzuki, Kensuke
    Nakada, Shinichiro
    Ohtsuka, Masayuki
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (10) : 6992 - 7000
  • [39] Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Satoi, S.
    Yamamoto, T.
    Uchida, K.
    Fujii, T.
    Kin, T.
    Asano, T.
    Hanada, K.
    Itoi, T.
    Murakami, Y.
    Igarashi, H.
    Eguchi, H.
    Kuroki, T.
    Shimizu, Y.
    Tani, M.
    Tanno, S.
    Tsuji, Y.
    Hirooka, Y.
    Masamune, A.
    Mizumoto, K.
    Shimokawa, T.
    Yamaue, H.
    Okazaki, K.
    PANCREAS, 2019, 48 (10) : 1516 - 1517
  • [40] Sphingosine Kinase Expression Is Associated With Poor Prognosis In Resectable Pancreatic Ductal Adenocarcinoma
    Jamieson, N. B.
    Carter, C. R.
    Dickson, E. J.
    Edwards, J.
    McKay, C. J.
    PANCREAS, 2012, 41 (08) : 1369 - 1369
12345